Encompass Health (NYSE:EHC) Price Target Increased to $108.00 by Analysts at Barclays

Encompass Health (NYSE:EHC) had its target price raised by investment analysts at Barclays from $101.00 to $108.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 31.37% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on EHC. Mizuho boosted their target price on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial boosted their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a report on Friday, February 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $83.00 price target on shares of Encompass Health in a report on Friday, February 9th. Stephens reaffirmed an “overweight” rating and issued a $85.00 price target on shares of Encompass Health in a report on Tuesday, January 16th. Finally, William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a report on Wednesday, February 7th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $85.44.

Encompass Health Stock Performance

Shares of NYSE EHC traded down $0.59 during midday trading on Thursday, reaching $82.21. The company’s stock had a trading volume of 637,626 shares, compared to its average volume of 660,989. Encompass Health has a 12-month low of $57.55 and a 12-month high of $85.84. The firm has a 50 day moving average price of $77.89 and a 200-day moving average price of $70.67. The stock has a market capitalization of $8.23 billion, a P/E ratio of 23.69, a PEG ratio of 1.53 and a beta of 0.94. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.28 and a quick ratio of 1.28.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.19. The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. Encompass Health’s revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.88 EPS. As a group, equities analysts predict that Encompass Health will post 3.96 earnings per share for the current year.

Institutional Trading of Encompass Health

Several institutional investors have recently added to or reduced their stakes in EHC. International Assets Investment Management LLC purchased a new stake in shares of Encompass Health during the fourth quarter worth about $20,210,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Encompass Health by 2.3% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company’s stock worth $87,989,000 after purchasing an additional 29,926 shares during the period. Phocas Financial Corp. boosted its holdings in shares of Encompass Health by 112.4% during the fourth quarter. Phocas Financial Corp. now owns 99,875 shares of the company’s stock worth $6,664,000 after purchasing an additional 52,847 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Encompass Health by 21.0% during the fourth quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock worth $6,787,000 after purchasing an additional 17,684 shares during the period. Finally, Oak Thistle LLC boosted its holdings in shares of Encompass Health by 19.1% during the fourth quarter. Oak Thistle LLC now owns 14,436 shares of the company’s stock worth $963,000 after purchasing an additional 2,319 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.